Increased development of radiographic hip osteoarthritis in individuals with high bone mass: a prospective cohort study.


Journal

Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438

Informations de publication

Date de publication:
06 01 2021
Historique:
received: 20 08 2020
accepted: 09 11 2020
entrez: 7 1 2021
pubmed: 8 1 2021
medline: 22 6 2021
Statut: epublish

Résumé

Individuals with high bone mass (HBM) have a greater odds of prevalent radiographic hip osteoarthritis (OA), reflecting an association with bone-forming OA sub-phenotypes (e.g. osteophytosis, subchondral sclerosis). As the role of bone mineral density (BMD) in hip OA progression is unclear, we aimed to determine if individuals with HBM have increased incidence and/or progression of bone-forming OA sub-phenotypes. We analysed an adult cohort with and without HBM (L1 and/or total hip BMD Z-score > + 3.2) with pelvic radiographs collected at baseline and 8-year follow-up. Sub-phenotypes were graded using the OARSI atlas. Superior/inferior acetabular/femoral osteophyte and medial/superior joint space narrowing (JSN) grades were summed and Δosteophyte and ΔJSN derived. Pain and functional limitations were quantified using the WOMAC questionnaire. Associations between HBM status and change in OA sub-phenotypes were determined using multivariable linear/logistic regression, adjusting for age, sex, height, total body fat mass, follow-up time and baseline sub-phenotype grade. Generalised estimating equations accounted for individual-level clustering. Of 136 individuals, 62% had HBM at baseline, 72% were female and mean (SD) age was 59 (10) years. HBM was positively associated with both Δosteophytes and ΔJSN (adjusted mean grade differences between individuals with and without HBM β HBM is associated with the worsening of hip osteophytes and JSN over an average of 8 years, as well as increased hip pain and functional limitation.

Sections du résumé

BACKGROUND
Individuals with high bone mass (HBM) have a greater odds of prevalent radiographic hip osteoarthritis (OA), reflecting an association with bone-forming OA sub-phenotypes (e.g. osteophytosis, subchondral sclerosis). As the role of bone mineral density (BMD) in hip OA progression is unclear, we aimed to determine if individuals with HBM have increased incidence and/or progression of bone-forming OA sub-phenotypes.
METHODS
We analysed an adult cohort with and without HBM (L1 and/or total hip BMD Z-score > + 3.2) with pelvic radiographs collected at baseline and 8-year follow-up. Sub-phenotypes were graded using the OARSI atlas. Superior/inferior acetabular/femoral osteophyte and medial/superior joint space narrowing (JSN) grades were summed and Δosteophyte and ΔJSN derived. Pain and functional limitations were quantified using the WOMAC questionnaire. Associations between HBM status and change in OA sub-phenotypes were determined using multivariable linear/logistic regression, adjusting for age, sex, height, total body fat mass, follow-up time and baseline sub-phenotype grade. Generalised estimating equations accounted for individual-level clustering.
RESULTS
Of 136 individuals, 62% had HBM at baseline, 72% were female and mean (SD) age was 59 (10) years. HBM was positively associated with both Δosteophytes and ΔJSN (adjusted mean grade differences between individuals with and without HBM β
CONCLUSIONS
HBM is associated with the worsening of hip osteophytes and JSN over an average of 8 years, as well as increased hip pain and functional limitation.

Identifiants

pubmed: 33407835
doi: 10.1186/s13075-020-02371-0
pii: 10.1186/s13075-020-02371-0
pmc: PMC7788917
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4

Subventions

Organisme : Versus Arthritis
ID : 20000
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00011/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 20378/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 080280/Z/06/Z
Pays : United Kingdom

Références

Ann Rheum Dis. 2013 Jun;72(6):918-23
pubmed: 22730371
Hum Mol Genet. 2017 Oct 1;26(19):3850-3858
pubmed: 28934396
J Rheumatol. 1999 Mar;26(3):622-6
pubmed: 10090173
Osteoarthritis Cartilage. 2014 Aug;22(8):1120-8
pubmed: 24971870
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Pain. 2015 Jun;156(6):1161-70
pubmed: 25659070
Arthritis Rheum. 1996 Jan;39(1):81-6
pubmed: 8546742
Osteoarthritis Cartilage. 2007;15 Suppl A:A1-56
pubmed: 17320422
J Clin Densitom. 2010 Jan-Mar;13(1):24-28
pubmed: 20171566
Hum Mol Genet. 2017 Oct 1;26(R2):R193-R201
pubmed: 28977450
J Bone Miner Res. 2020 Jan;35(1):92-105
pubmed: 31525280
Osteoporos Int. 2012 Feb;23(2):643-54
pubmed: 21455762
BMJ. 2015 Dec 03;351:h6262
pubmed: 26635241
J Rheumatol. 1988 Dec;15(12):1833-40
pubmed: 3068365
J Bone Miner Res. 2012 Oct;27(10):2208-16
pubmed: 22623101
Arthritis Rheum. 2009 Jul;60(7):2028-36
pubmed: 19565486
Osteoporos Int. 2010 Jul;21(7):1227-36
pubmed: 19859644
J Bone Joint Surg Am. 2009 Feb;91 Suppl 1:54-62
pubmed: 19182026
Arthritis Rheumatol. 2019 Mar;71(3):361-369
pubmed: 30264891
Ann Rheum Dis. 2015 Feb;74(2):347-53
pubmed: 24243926
Arthritis Rheum. 2011 Nov;63(11):3392-400
pubmed: 21739424
Med Sci Sports Exerc. 2004 Mar;36(3):556
pubmed: 15076800
Am J Hum Genet. 2002 Jan;70(1):11-9
pubmed: 11741193
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Ann Rheum Dis. 2002 Feb;61(2):145-50
pubmed: 11796401
Osteoporos Int. 2010 Aug;21(8):1307-16
pubmed: 20101493
J Rheumatol Suppl. 2004 Apr;70:6-9
pubmed: 15132348
Am J Epidemiol. 1990 Sep;132(3):514-22
pubmed: 2389755
Arthritis Rheumatol. 2014 Sep;66(9):2429-39
pubmed: 24910132
Arthritis Care Res (Hoboken). 2017 Dec;69(12):1863-1870
pubmed: 28129489
J Bone Joint Surg Br. 2003 Jul;85(5):706-11
pubmed: 12892194
Osteoarthritis Cartilage. 2017 Sep;25(9):1478-1483
pubmed: 28336452
Bone. 2018 Sep;114:62-71
pubmed: 29883787
J Bone Miner Res. 1997 Aug;12(8):1316-7
pubmed: 9258764
Arthritis Rheum. 1995 Jul;38(7):907-16
pubmed: 7612040
BMJ. 2015 Dec 02;351:h5983
pubmed: 26631296
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Public Health Nutr. 2006 Sep;9(6):755-62
pubmed: 16925881
Arthritis Rheum. 2000 Jul;43(7):1450-5
pubmed: 10902745
Ann Rheum Dis. 2014 Jul;73(7):1323-30
pubmed: 24553908
J Clin Endocrinol Metab. 2013 Feb;98(2):818-28
pubmed: 23337721
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834

Auteurs

April Hartley (A)

Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. april.hartley@bristol.ac.uk.
MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. april.hartley@bristol.ac.uk.

Sarah A Hardcastle (SA)

Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Royal National Hospital for Rheumatic Diseases, Royal United Hospitals Bath NHS Foundation Trust, Bath, UK.

Monika Frysz (M)

Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Jon Parkinson (J)

Division of Informatics, Imaging & Data Sciences, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK.

Lavinia Paternoster (L)

MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Eugene McCloskey (E)

Academic Unit of Bone Metabolism, Department of Oncology and Metabolism, The Mellanby Centre For Bone Research, University of Sheffield, Sheffield, UK.
Centre for Metabolic Diseases, University of Sheffield Medical School, Sheffield, UK.
Centre for Integrated Research into Musculoskeletal Ageing, University of Sheffield Medical School, Sheffield, UK.

Kenneth E S Poole (KES)

Cambridge NIHR Biomedical Research Centre and the Wellcome Trust Clinical Research Facility, Cambridge, UK.

Muhammad K Javaid (MK)

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Mo Aye (M)

Department of Diabetes, Endocrinology and Metabolism, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK.

Katie Moss (K)

Centre for Rheumatology, St George's Hospital, St George's Healthcare NHS Trust, London, UK.

Martin Williams (M)

Department of Radiology, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.

Jon H Tobias (JH)

Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Celia L Gregson (CL)

Musculoskeletal Research Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH